EASTERN PEDIATRIC ONCOLOGY CONSORTIUM

东部儿科肿瘤组联盟（EPOC）由以下成员组成： 西奈山医学院儿科血液学/肿瘤学分部 医学（MSSM），耶鲁大学医学院（YUSM）， 马里兰州医学院（UMSM）和马萨诸塞州大学 医学院（UMMS）正式成立了一个长期的知识分子 四位主要研究者之间的关系 机构职能体系EPOC存在的理由是， 希望我们在POG内合作的四个机构将 如果我们继续运作， 分开该集团的长期目标是利用我们的 基础和临床药理学、流式细胞术、 神经母细胞瘤和骨髓细胞分子生物学 移植具体而言，我们将（l）开发和参与新的 神经母细胞瘤和其他肿瘤的生物学治疗方法 儿童胚胎性肿瘤具体的试点研究将包括一个阶段 硝酸镓的I期研究，9-顺式视黄酸的I期研究， 神经母细胞瘤的基于细胞周期的新治疗方法， 生长因子拮抗剂的化学增敏作用。(2)增强少数民族 参与POG研究，特别是I期研究。（三） 继续在药理学领域的POG中发挥领导作用， 神经母细胞瘤、骨肿瘤、骨髓移植和非霍奇金淋巴瘤 淋巴瘤（4）参与POG的管理功能， 骨髓移植、新药和药理学领域， 非霍奇金淋巴瘤

The Eastern Pediatric Oncology Group Consortium (EPOC) consisting of the Division of Pediatric Hematology/Oncology of the Mount Sinai School of Medicine (MSSM), Yale University School of Medicine (YUSM), University of Maryland School of Medicine (UMSM), and University of Massachusetts Medical School (UMMS) formalizes a long standing intellectual relationship between the Principal Investigators of the four institutions. The rationale for the existence of EPOC rests upon the expectation that our four institutions working together within POG will contribute more to the group than would occur if we continued to function separately. The long term objectives of the group are to make use of our scientific expertise in basic and clinical pharmacology, flow cytometry, cellular and molecular biology of neuroblastoma and bone marrow transplantation. Specifically, we will (l) develop and participate in new biologically based therapeutic approaches to neuroblastoma and other embryonal tumors of children. Specific pilot studies will include a phase I study of Gallium Nitrate, a phase I Study of 9-cis retinoic acid and novel cell cycle based therapeutic approaches to neuroblastoma involving chemosensitization with growth factor antagonists. (2) enhance minority participation in POG studies and in particular phase I studies. (3) continue to provide leadership in POG in the areas of pharmacology, neuroblastoma, bone tumors, bone marrow transplantation and non-Hodgkin's lymphoma (4) participate in the administrative functions of POG in the areas of bone marrow transplantation, new agents and pharmacology and non-Hodgkin's lymphoma.